Diabetes
Conditions
Brief summary
Assessment of the system accuracy of different blood glucose monitoring systems available in Europe
Detailed description
A variety of blood glucose monitoring systems (BGMS) are available on the European market. For many of these BGMS, the system accuracy is unknown or it has not yet been assessed in manufacturer-independent studies. The IDT surveillance program aims at assessing the system accuracy of different BGMS that are available in Europe in a manufacturer-independent, investigator-initiated study. The initial study will cover 18 BGMS from 18 different manufacturers. Per BGMS, one test strip lot will be assessed based on procedures stated in the international standard ISO 15197:2013 / EN ISO 15197:2015.
Interventions
Capillary blood samples will be used for the evaluation of system accuracy.
Sponsors
Institut für Diabetes-Technologie Forschungs- und Entwicklungsgesellschaft mbH an der Universität Ulm
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Male or female, with type 1 diabetes, type 2 diabetes or subjects without diabetes * Signed informed consent form * Minimum age of 18 years * ubjects are legally competent and capable to understand character, meaning and consequences of the study. * If blood glucose values \< 80 mg/dl or \> 300 mg/dl shall be measured after short term alteration in insulin therapy: * Male or female with type 1 diabetes and intensified insulin therapy or insulin pump therapy. * Signature of subjects to document consent with these procedures on informed consent form.
Exclusion criteria
* Pregnancy or lactation period * Severe acute disease (at the study physician's discretion) * Severe chronic disease with potential risk during the test procedures (at the study physician's discretion) * Current constitution that compromises the subject's capability to participate in the study (at the study physician's discretion) * Being unable to give informed consent * \< 18 years * Legally incompetent * Being committed to an institution (e.g. psychiatric clinic) * Language barriers potentially compromising an adequate compliance with study procedures * Dependent on investigator or sponsor * If blood glucose values \< 80 mg/dl shall be measured after short term alteration in insulin therapy, subjects with type 1 diabetes, suffering from: * Coronary heart disease * Condition after myocardial infarction * Condition after cerebral events * Peripheral arterial occlusive disease * Hypoglycemia unawareness
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Analysis of system accuracy based on ISO 15197 | For each subject, the experimental phase has an expected duration of up to 6 hours | Assessment of the analytical measurement performance of 18 blood glucose montoring systems based on procedures defined in ISO 15197 |
Countries
Germany
Outcome results
None listed